Treatment of Severe Hypertension During Pre-Eclampsia: A Preliminary Equivalence Study Between Urapidil and Nicardipine
- Sponsor
- University Hospital, Strasbourg, France
- Study ID
- NCT00409253
- Phase
- PHASE3
- Status
- Unknown
Conditions
- Hypertension During Pre-Eclampsia
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 51 Years
- Healthy Volunteers
- Not accepted
Interventions
- URAPIDIL (EUPRESSYL*) — DRUGUrapidil (Eupressyl\*) :IV (PSE) 1 microg/kg/min° until reduction PAM 15 %. Reduction ¼ of the posology to obtain PAM between 105 and 125 mmHg with adjustment 0.25 microg/kg/min/15 min. Maximal dose = 30mg/h.
- NICARDIPINE — DRUGNicardipine : IV 6.25 mg bolus until PAD \>105 mm/Hg. Perfusion (PSE) 4 mg/h to obtain PAM between 105 and 125 mm/Hg with adjustment 2mg/h/5 min without overshoot 20 mg/h Maximal treatment duration : 7 days
Study Details
The aim of this study is to confirm that URAPIDIL is as efficient and as safe as NICARDIPINE to correct severe hypertension in pre-eclamptic patients. * efficacy endpoint : mean arterial blood pressure corrected to 105-125 mmHg after 120 min of study drug administration. * safety endpoints : clinical, biological and ultrasound observation for any side effect.All infants will be observed in the neonatology unit (during 48h).
Key Dates
- Start date
- Jun 30, 2007
- Status verified
- Feb 2009
- Primary completion
- Jun 30, 2010
- Completion
- Aug 31, 2010
Study Design
- Enrollment
- 72 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Urapidil
- Active Comparator: Nicardipine
Primary Outcome Measure
Systolic, diastolic, mean blood pressure and pulse rate :-every 5 min during the titration phase-every 15 min up to the second hour treatment-every hour up to the 6th hour and every 3 hour during the rest of the treatment period. [ Time Frame: Systolic, diastolic, mean blood pressure and pulse rate :-every 5 min during the titration phase-every 15 min up to the second hour treatment-every hour up to the 6th hour and every 3 hour during the rest of the treatment period ]
Central Contacts
- Pierre Auguste DIEMUNSCH, MD33.3.88.12.70.78